BRAF and non-small cell lung carcinoma: However, the response to BRAF inhibitor monotherapy in NSCLC with the BRAF V600E mutation has been less than optimal, with ORRs ranging between 33% and 42%, and a median progression-free survival (PFS) of only about 5.5 to 7.3 months (18–20).